Incubation of Lymphocytes with IL-2 Causes the Appearance of Antitumor T Cells Carrying FC, CD25, and LFA-1 on the Surface

To carry out antitumor activity against cells that have lost surface antigens, human lymphocytes must have a certain repertoire of surface proteins capable of contacting a tumor cell and inducing programmed cell death in it. In this work, we showed that activation of healthy donor cells by IL-2 cyto...

Full description

Saved in:
Bibliographic Details
Published in:Doklady. Biochemistry and biophysics 2023-02, Vol.508 (1), p.12-16
Main Authors: Ivanova, O. K., Sharapova, T. N., Romanova, E. A., Yashin, D. V., Sashchenko, L. P.
Format: Article
Language:English
Subjects:
Antigens
Antitumor activity
Apoptosis
Biochemistry
Biochemistry, Biophysics, and Molecular Biology
Biological and Medical Physics
Biomedical and Life Sciences
Biophysics
CD25 antigen
CD8 antigen
CD8-Positive T-Lymphocytes
Cell activation
Cell death
Cytokines
FasL protein
Humans
Intercellular adhesion molecule 1
Interleukin 2
Interleukin-2 - metabolism
LFA-1 antigen
Life Sciences
Lymphocyte Function-Associated Antigen-1 - metabolism
Lymphocytes T
Molecular Biology
Surface antigens
T-Lymphocytes - immunology
Tumor cells
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To carry out antitumor activity against cells that have lost surface antigens, human lymphocytes must have a certain repertoire of surface proteins capable of contacting a tumor cell and inducing programmed cell death in it. In this work, we showed that activation of healthy donor cells by IL-2 cytokine within 6 days causes the appearance of FasL, CD25, and LFA-1 proteins on CD8+CD25+ T lymphocytes, and also converts the LFA-1 protein into an active form having a high affinity for its target, ICAM-1 integrin. The appearance of these proteins on the surface of this subpopulation of lymphocytes allows them to induce programmed cell death in HLA-negative tumor cells.
ISSN:1607-6729
1608-3091
DOI:10.1134/S160767292270003X